This on-demand webinar helps answer the question, “What constitutes quality allogeneic cell therapy starting material and how you can ensure it?”

The webinar explores specific risks and practical downstream repercussions of insufficient and variable starting material quality. Our expert panelists discuss how to help ensure both high-quality and consistent cellular starting material by building efficiencies into, and alleviating bottlenecks within, the cell harvest infrastructure.

Plus, gain insights into critical considerations when determining an optimal starting material supplier.

Our panel of experts include:

  • Philippe Parone, PhD, Industrialization Director, Celyad
  • Marty Giedlin, PhD, Senior Vice President, Process Development, PACT Pharma Inc.
  • Chris McClain, MBA, Senior Vice President, Sales & Business Development, NMDP BioTherapies (formerly Be The Match BioTherapies)
  • Behnam Ahmadian Baghbaderani, PhD, Head, Process Development for Cell & Gene Technologies, Lonza


View Webinar